乳腺癌患者新辅助化疗后 MR 成像完全缓解:影像-病理不一致的相关因素
该回顾性研究纳入 209 例新辅助化疗后 MR 成像显示影像学完全缓解的连续乳腺癌患者,评估影像-病理不一致(假阴性)的放射学与临床病理因素。病理完全缓解 108 例(51.7%),残留病变 101 例(48.3%);组织学分级 1 或 2 级、低肿瘤浸润淋巴细胞、Luminal A 或 B 亚型及乳腺X线钙化、多灶多中心病变、治疗前 MR 非肿块强化与假阴性显著相关。作者认为这些人群判读时应谨慎。
要点
- 新辅助化疗后 MR 显示无强化判为影像学完全缓解,但 48.3%(101/209)病理仍有残留。
- 乳腺X线钙化、多灶多中心病变、治疗前 MR 非肿块强化是假阴性的独立预测因素。
- 组织学 1–2 级、低肿瘤浸润淋巴细胞、Luminal A/B 亚型者假阴性更常见。
核心结论
- 乳腺X线钙化、多灶多中心病变及治疗前 MR 非肿块强化与 new adjuvant chemotherapy 后 MR 影像学完全缓解者的假阴性结果显著相关,此类人群判读应谨慎。
研究设计与样本
- 回顾性研究,经机构审查委员会批准,连续纳入 209 例新辅助化疗后 MR 成像显示影像学完全缓解的乳腺癌患者;影像学完全缓解定义为原病灶部位无强化;病理完全缓解定义为病理上乳腺内浸润癌及导管原位癌均完全缺失。
关键影像表现/征象
- 影像学完全缓解判为原病灶部位无强化,但 101/209(48.3%)病理存在残留病变。
- 乳腺X线显示钙化与假阴性结果显著相关(p = 0.037)。
- 多灶多中心病变与假阴性结果显著相关(p = 0.004)。
- 治疗前 MR 显示非肿块强化与假阴性结果显著相关(p = 0.023)。
诊断标准与关键数值
- 影像学完全缓解标准:原病灶部位无强化。
- 病理完全缓解标准:病理上乳腺内浸润癌及导管原位癌均完全缺失。
- 病理完全缓解 108/209(51.7%),残留病变 101/209(48.3%)。
- 假阴性在组织学 1 或 2 级(p = 0.001)、低肿瘤浸润淋巴细胞(p = 0.004)、Luminal A 或 B 亚型(p < 0.001)中更常见。
临床应用与阅片要点
- 对乳腺X线有钙化、多灶多中心病变或治疗前 MR 非肿块强化的患者,新辅助化疗后 MR 判为影像学完全缓解时作者认为应谨慎判读。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the radiologic and clinicopathologic factors in radiologic-pathologic discordance (false-negative results) in breast cancer patients who demonstrate radiologic complete response (rCR) in MR imaging after neoadjuvant chemotherapy (NAC).
METHOD: Our institutional review board approved this retrospective study. We included 209 consecutive patients who showed rCR in MR imaging after NAC. rCR was diagnosed when the original lesion site showed no enhancement. Pathologic CR (pCR) was defined as the complete absence of both invasive cancer and ductal carcinoma in situ in the breast upon pathology. Clinicopathologic and radiologic factors affecting the radiologic-pathologic correlation were analyzed.
RESULTS: pCR was noted in 108 patients (51.7%); the remaining 101 (48.3%) had residual lesion on pathology. False negative rCR findings were significantly more frequent in cases of 1 or 2 histologic grade (p = 0.001), low tumor-infiltrating lymphocytes (p = 0.004), and luminal A or B subtype (p < 0.001). Multivariate analysis of radiologic findings to identify predictors of false negative findings found calcifications in mammography (p = 0.037), multifocal multicentric lesions (p = 0.004), and non-mass enhancement in pretreatment MR imaging (p = 0.023) to be significantly associated with false-negative findings.
CONCLUSIONS: Patients with calcification in mammography, multifocal multicentric lesions, and non-mass enhancement in pretreatment MR imaging are significantly associated with false-negative results who showed rCR on MR imaging after NAC. These patient populations should be interpreted with caution.
引用
- Choi WJ, Kim HH, Cha JH, et al. Complete response on MR imaging after neoadjuvant chemotherapy in breast cancer patients: Factors of radiologic-pathologic discordance. Eur J Radiol. 2019. PMID: 31439230. doi:10.1016/j.ejrad.2019.06.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。